| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
|
Lancet
|
2012
|
12.00
|
|
2
|
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.
|
Int J Clin Oncol
|
2011
|
5.39
|
|
3
|
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
|
N Engl J Med
|
2015
|
3.09
|
|
4
|
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.
|
Int J Clin Oncol
|
2015
|
2.70
|
|
5
|
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
|
Gastric Cancer
|
2006
|
1.60
|
|
6
|
Predictors for early recurrence after hepatectomy for initially unresectable colorectal liver metastasis.
|
J Gastrointest Surg
|
2013
|
1.45
|
|
7
|
Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan.
|
J Gastroenterol Hepatol
|
2007
|
1.42
|
|
8
|
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2015
|
1.39
|
|
9
|
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status.
|
Curr Colorectal Cancer Rep
|
2013
|
1.12
|
|
10
|
Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients.
|
Gastric Cancer
|
2012
|
1.04
|
|
11
|
[High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer].
|
Gan To Kagaku Ryoho
|
2011
|
1.03
|
|
12
|
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
|
Cancer Chemother Pharmacol
|
2011
|
1.03
|
|
13
|
Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma.
|
Intern Med
|
2011
|
1.02
|
|
14
|
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
|
BMC Cancer
|
2013
|
0.99
|
|
15
|
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.96
|
|
16
|
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
|
Jpn J Clin Oncol
|
2012
|
0.95
|
|
17
|
KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study.
|
Jpn J Clin Oncol
|
2013
|
0.94
|
|
18
|
A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2009
|
0.93
|
|
19
|
Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
|
Gastric Cancer
|
2006
|
0.91
|
|
20
|
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
|
Jpn J Clin Oncol
|
2011
|
0.91
|
|
21
|
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Sci
|
2014
|
0.90
|
|
22
|
Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
|
Jpn J Clin Oncol
|
2010
|
0.89
|
|
23
|
Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.
|
Jpn J Clin Oncol
|
2014
|
0.87
|
|
24
|
Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
|
Jpn J Clin Oncol
|
2013
|
0.87
|
|
25
|
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2008
|
0.86
|
|
26
|
Distribution and prevalence of colorectal hyperplastic polyps using magnifying pan-mucosal chromoendoscopy and its relationship with synchronous colorectal cancer: prospective study.
|
J Gastroenterol Hepatol
|
2005
|
0.85
|
|
27
|
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
|
Jpn J Clin Oncol
|
2009
|
0.84
|
|
28
|
Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.
|
J Biosci Bioeng
|
2013
|
0.84
|
|
29
|
Adenocarcinoma in solitary large hyperplastic polyp diagnosed by magnifying colonoscope: report of a case.
|
Dis Colon Rectum
|
2002
|
0.83
|
|
30
|
Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.
|
Jpn J Clin Oncol
|
2010
|
0.83
|
|
31
|
Early colon cancers detected by FDG-pet: a report of two cases with immunohistochemical investigation.
|
Hepatogastroenterology
|
2004
|
0.82
|
|
32
|
Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
|
Cancer Sci
|
2015
|
0.82
|
|
33
|
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
|
Oncologist
|
2014
|
0.82
|
|
34
|
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
|
Cancer Chemother Pharmacol
|
2015
|
0.81
|
|
35
|
[Spindle cell sarcoma of the penis: a case report].
|
Hinyokika Kiyo
|
2012
|
0.81
|
|
36
|
Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.
|
Drug Metab Pharmacokinet
|
2009
|
0.81
|
|
37
|
A novel endoscopic device for retrieval of polyps resected from the colon and rectum.
|
Gastrointest Endosc
|
2004
|
0.80
|
|
38
|
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
|
Jpn J Clin Oncol
|
2010
|
0.80
|
|
39
|
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
|
Int J Clin Oncol
|
2008
|
0.80
|
|
40
|
A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
41
|
Depressed-type (0-IIc) colorectal neoplasm in patients with family history of first-degree relatives with colorectal cancer: A cross-sectional study.
|
World J Gastroenterol
|
2006
|
0.80
|
|
42
|
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
|
Jpn J Clin Oncol
|
2011
|
0.80
|
|
43
|
A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.79
|
|
44
|
Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies.
|
Jpn J Clin Oncol
|
2012
|
0.79
|
|
45
|
Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
|
Jpn J Clin Oncol
|
2009
|
0.79
|
|
46
|
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.78
|
|
47
|
Small cell carcinoma of the esophagus responding to fourth-line chemotherapy with weekly paclitaxel.
|
Int J Clin Oncol
|
2005
|
0.78
|
|
48
|
Incidence and localization of lymphoid follicles in early colorectal neoplasms.
|
World J Gastroenterol
|
2005
|
0.78
|
|
49
|
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.78
|
|
50
|
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
|
Anticancer Drugs
|
2015
|
0.77
|
|
51
|
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.77
|
|
52
|
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.
|
Immunogenetics
|
2012
|
0.77
|
|
53
|
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2013
|
0.77
|
|
54
|
[Efficacy of TAS-102].
|
Gan To Kagaku Ryoho
|
2015
|
0.76
|
|
55
|
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.76
|
|
56
|
Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients.
|
Drug Metab Pharmacokinet
|
2011
|
0.76
|
|
57
|
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.
|
Invest New Drugs
|
2015
|
0.76
|
|
58
|
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
59
|
Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.
|
Drug Metab Pharmacokinet
|
2010
|
0.75
|
|
60
|
Superficially elevated colonic adenoma changed to undetectable configuration on ordinary endoscopy during treatment with preferential cyclooxygenase-2 inhibitor.
|
J Gastroenterol
|
2003
|
0.75
|
|
61
|
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
62
|
[Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].
|
Nihon Rinsho
|
2011
|
0.75
|
|
63
|
[Clinical development of biomarkers for personalized medicine].
|
Nihon Rinsho
|
2010
|
0.75
|
|
64
|
[Current Status and Future Perspectives of SCRUM-Japan].
|
Gan To Kagaku Ryoho
|
2017
|
0.75
|
|
65
|
The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients.
|
Clin Lab
|
2016
|
0.75
|
|
66
|
The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer.
|
Jpn J Clin Oncol
|
2007
|
0.75
|
|
67
|
Management of ureteral obstruction in advanced testicular tumor with lymph node metastasis.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
68
|
[Bevacizumab (Avastin)].
|
Gan To Kagaku Ryoho
|
2007
|
0.75
|
|
69
|
[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
|
Gan To Kagaku Ryoho
|
2009
|
0.75
|
|
70
|
[Endoscopic therapy for colorectal cancer].
|
Nihon Rinsho
|
2003
|
0.75
|
|
71
|
[Predictive biomarkers for anti-EGFR antibodies].
|
Gan To Kagaku Ryoho
|
2012
|
0.75
|
|
72
|
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
|
J Gastroenterol
|
2008
|
0.75
|
|
73
|
[Conversion therapy for colorectal cancer].
|
Gan To Kagaku Ryoho
|
2011
|
0.75
|
|
74
|
[Chemotherapeutic agents and electrolyte imbalance].
|
Nihon Rinsho
|
2015
|
0.75
|
|
75
|
[IFL].
|
Gan To Kagaku Ryoho
|
2006
|
0.75
|